The Effect of AMG 133 on Gastric Emptying

Part of paid clinical trials in Daytona Beach, Florida.

Sponsor
Amgen
Study ID
NCT07429032
Phase
PHASE1
Status
Completed

Conditions

  • Overweight or Obesity

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • AMG 133 — DRUG
    AMG 133 will be administered SC.
  • Placebo — DRUG
    Placebo will be administered SC.
  • Acetaminophen — DRUG
    Acetaminophen will be administered orally.

Study Details

The primary objective of the trial is to evaluate the effect of AMG 133 versus placebo on acetaminophen pharmacokinetics (PK), a marker for gastric emptying, in participants living with overweight or obesity.

Key Dates

Start date
Apr 17, 2025
Status verified
Dec 2025
Primary completion
Nov 26, 2025
Completion
Nov 26, 2025

Study Design

Enrollment
57 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: AMG 133
    Participants will receive AMG 133 subcutaneously (SC) and acetaminophen orally.
  • Placebo Comparator: Placebo
    Participants will receive placebo SC and acetaminophen orally.

Primary Outcome Measure

Maximum Observed Plasma Concentration (Cmax) for Acetaminophen [ Time Frame: Days 1, 3, 8, 17, 31, 59, 64, and 86 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research Unit - Daytona BeachDaytona BeachFlorida32117-

Find similar trials in Daytona Beach, FL

By research site
Fortrea Clinical Research Unit - Daytona Beach· Daytona Beach, FL

Related Studies